Acute and 6-month clinical and angiographic outcome after implantation of the ACS Duet stent for single-vessel coronary artery disease: final results of the European and US ACS Multi-link Duet Registry
| Autor: | Dean Kererakes, Stan Fink, Diederik van Hoogenhuyze, Alexandra M. Lansky, David P. Foley, Michael J.B. Kutryk, Naomi Nishimura, Alan C. Yeung, Susan Veldhof, Patrick W. Serruys, Gerrit-Anne van Es, Jan A.M. te Riele |
|---|---|
| Přispěvatelé: | Cardiology |
| Rok vydání: | 2001 |
| Předmět: |
Male
medicine.medical_specialty Time Factors Endpoint Determination medicine.medical_treatment Coronary Disease Coronary Angiography Prosthesis Implantation Coronary artery disease Angina Restenosis Internal medicine Angioplasty Coronary stent medicine Humans Radiology Nuclear Medicine and imaging Prospective Studies Registries Angioplasty Balloon Coronary Ticlopidine Aged medicine.diagnostic_test business.industry Stent Equipment Design General Medicine Length of Stay Middle Aged medicine.disease Survival Analysis United States Surgery Europe Treatment Outcome Angiography Cardiology Female Stents Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Catheterization and Cardiovascular Interventions, 54(1), 25-33. Wiley-Liss Inc. |
| ISSN: | 1522-1946 |
| Popis: | The aim of the study was to determine the safety and efficacy of the second-generation ACS Multi-Link Duet coronary stent system for the treatment of single, symptomatic, de novo, native coronary artery lesions. Between February and June 1998, 427 patients (69.3% male, 51.5% class 3 or 4 angina, 20.1% diabetic, 43.6% hyperlipidemia) were included at 38 centers in this prospective observational study. All patients received ticlopidine 500 mg/day for 1 month and aspirin > or =100 mg/day. The Duet stent was available in 8, 18, and 28 mm length and 3.0, 3.5, and 4.0 mm diameter. After adequate predilatation, stents were successfully implanted, at up to 16 atm, in 99.3% of patients. Mean vessel diameter by core laboratory quantitative coronary angiography was 3.0 +/- 0.53 mm and postprocedural minimum luminal diameter was 2.79 +/- 0.43 mm (12% +/- 9.3% diameter stenosis). At 30 days, 96.7% of patients were event-free and at 6 months 88.1% remained free of major adverse cardiac events. The restenosis rate was 18.1%. The ACS Duet stent was safely implanted in >99% of target lesions by a diverse group of international investigators. With late outcomes at least comparable to the best published results, this stent platform provides safe and effective percutaneous treatment of obstructive coronary artery disease. Cathet Cardiovasc Intervent 2001;54:25-33. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text